Optimization of 131I ablation in patients with differentiated thyroid carcinoma: Comparison of early outcomes of treatment with 100 mCi versus 60 mCi;Optymalizacja leczenia uzupełniaja̧cego jodem promieniotwórczym u chorych na zróżnicowanego raka tarczycy: porównanie wczesnych wyników leczenia aktywnościa̧ 100 mCi i 60 mCi

Endokrynologia Polska

Volumn 57, Issue 4, 2006, Pages 374-379

  Kukulska, Aleksandra ^a   Krajewska, Jolanta ^a   Roskosz, Józef ^a   Handkiewicz Junak, Daria ^a   Jarza̧b, Michał ^a   Paliczka, Ewa ^a   Puch, Zbigniew ^a   Wygoda, Zbigniew ^a   Gubała, Elzbieta ^a   Jarza̧b, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

131I remnant ablation; Differentiated thyroid cancer

Indexed keywords

RADIOACTIVE IODINE;

ADENOCARCINOMA; ADJUVANT THERAPY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; METASTASIS; METHODOLOGY; MINIMAL RESIDUAL DISEASE; PAPILLARY CARCINOMA; PROSPECTIVE STUDY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR RECURRENCE; WHOLE BODY COUNTING;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 39049189489     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9: 421-427.
2. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89 (8): 3668-3676.
3. Clarke SE. Radionuclide therapy of the thyroid. Eur J Nucl Med 1991; 18: 984-991.
4. Goolden AWG. The use of radioactive iodine in thyroid carcinoma. J Cancer Clin Oncol 1988; 24: 339-343.
5. Jarza̧b B, Roskosz J. Leczenie raka tarczycy izotopem jodu 131-I. Pol J Endocrinol 1995; 46/1 (supl. 2): 33-42.
6. McDougall RI. Thyroid disease in clinical practice. Chapman & Hall 1992.
7. Harvey D, Matheson NA, Grabowski PS i wsp. Measurement of serum thyroglobulin is of value in detecting tumor recurrence following treatment of differentiated thyroid carcinoma by lobectomy. Br J Surg 1990; 77: 324-326.
8. Schlumberger M, Fragu P, Garedet P i wsp. A new immunora-diometric assay (IRMA) system for follow-up of thyroid cancer patients. Eur J Med 1991; 18: 153-157.
9. Handkiewicz D, Gawkowska M, Roskosz J i wsp. Scyntygrafia 131I całego ciała po dawce terapeutycznej: ocena zysku diagnostycznego. Pol J Endocrinol 1995; 46/3 (supl. 2): 293.
10. McCowen KD, Adler RA, Ghaed N i wsp. Low dose radioiodine thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 1976; 61: 52-58.
11. Johansen K, Woodhouse N, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32(2): 252-254.
12. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265-271.
13. Jarza̧b B. Wskazania do leczenia jodem promieniotwórczym 131I w zróżnicowanym raku tarczycy. Wiad Lek 2001; 54 (supl. 1): 254-265.
14. Krajewska J, Czarniecka A, Roskosz J i wsp. Znaczenie pooperacyjne jodu promieniotwórczego w skojarzonym leczeniu zróżnicowanego raka tarczycy. III Konferencja naukowa "Rak Tarczycy" Szczyrk 23-25.03.06. Materiały zjazdowe.
15. Bal C, Padhy AK, Jana S. Prospective randomised clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 12: 2574-2580.
16. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocrine-Related Cancer 2004; 11: 97-116.
17. Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005; 46 (supl. 1): 28-33.
18. Schlumberger M, Pacini F, Wiersinga WM i wsp. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinology 2004; 151: 539-548.
19. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J of Nuclear Med 1999; 43: 313-323.
20. Urhan M, Mavi A, Fish S i wsp. Low versus high dose 131-I radioablation in post surgical management of differentiated thyroid carcinoma patients. Eur J Med Mol Imaging 2005; 32: 241.
21. Van Nostrand D, NeNeutze J, Atkins F. Side effects of rational dose iodine 131-therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 1986; 27: 1519-1527.
22. Puch Z, Roskosz J, Handkiewicz-Junak D. Ocena powikłań po leczeniu 131-I u chorych na zaawansowanego zróżnicowanego raka tarczycy. III Konferencja naukowa "Rak Tarczycy" Szczyrk 23-25.03.06. Materiały zjazdowe.
23. Gawkowska-Suwińska M. Centrum Onkologii, Instytut im. Marii Skłodowskiej-Curie 2003. Ocena wczesnej skuteczności leczenia uzupełniaja̧cego izotopem jodu 131I chorych na zróż nicowanego raka tarczycy. Praca Doktorska.
24. Pacini F, Molinaro E, Castagna MG i wsp. Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87 (9): 4063-4068.
25. Pacini F, Ladenson PW, Schlumberger M i wsp. Radioiodine ablation of thyroid remnants after preparation with recombi-nant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91 (3): 926-932.